Navigation Links
Autism Consortium members publish in PNAS: Mechanism, treatment for Rett syndrome -- top cause autism girls
Date:2/9/2009

Autism Consortium Scientists Publish Study Defining Mechanism and Potential Treatment for Rett Syndrome, Leading Cause of Autism in Girls

- Clinical trial to test molecule in humans is being planned - - Data in PNAS reveals therapeutic that could apply to other forms of autism -

BOSTON JANUARY 9, 2009 The Autism Consortium, an innovative research, clinical and family collaboration dedicated to radically accelerating research and enhancing clinical care for autism spectrum disorders (ASDs), announced today that several Consortium members published a paper with significance for clinical trials in autism in the Proceedings of the National Academy of Sciences.

The research led by Autism Consortium members Mriganka Sur, PhD, Newton Professor of Neuroscience at the Picower Institute and Head of the MIT Department of Brain and Cognitive Sciences; and Rudolf Jaenisch, PhD, Founding Member, Whitehead Institute and Professor of Biology at MIT, demonstrates for the first time a mechanism for Rett Syndrome and a therapeutic that could be directly applicable to humans. As a result, a clinical trial in humans is in development.

IGF1 Reverses Rett Symptoms in Mice; Clinical Trial Planned

This groundbreaking study demonstrated that by treating mice with a peptide fragment of IGF1, a molecule that is utilized by the brain for neuronal and synaptic development, the symptoms of Rett Syndrome in the mice were largely reversed.

"The next step is to test recombinant human IGF1 which is already available for pediatric use in humans with the hope of treating or reversing Rett Syndrome," said Omar Khwaja, MD, PhD, Director of the Rett Syndrome Program at Children's Hospital Boston and head of the clinical trial team for IGF1. "We are working as quickly possible to develop the protocol, secure funding, and initiate the trial."

"This new study presents promising novel data suggesting that targeting the IGF1 signaling axis may present a useful therapeutic strategy that could ultimately be translated to humans," said Dr. Antony Horton, Chief Scientific Officer at the International Rett Syndrome Foundation. "We are encouraged by this collaboration between scientists and clinicians which is yielding valuable insights into potential new treatments for Rett syndrome."

About Rett Syndrome and the Findings

Rett Syndrome, a neurodevelopmental disorder mainly affecting girls and also the most common basis of autism in girls, is primarily caused by a sporadic mutation in the MECP2 gene on the X chromosome. The MECP2 gene makes a protein, also called MeCP2, believed to play a pivotal role in silencing, i.e. turning off the activity of other genes. The MECP2 mutation causes the regulatory mechanism to fail, which in turn causes other genes to function abnormally.

Rett is a genetic disorder of developmental arrest or failure of brain maturation. This is thought to occur when subsets of neurons and their connections (synapses) are disrupted during a very dynamic phase of brain development. Scientists have been investigating ways to reverse that arrest and therefore, turn brain activity back on.

By crossing into the brain and activating 'IGF1 signaling' IGF1 binds to its receptor and activates downstream molecules within neurons that make synapses mature. This activity in turn ends the developmental arrest thought to underlie the syndrome.

Using mutant mice in which MeCP2 is deleted, Sur and his co-authors demonstrated a major underlying mechanism for the disordersynapses in the brain remain immature and showed persistent, abnormal plasticity into adulthood.

"Our research is beginning to show that other forms of autism also have, as their basis, this persistent immaturity of synapses," said Sur. "As a result, an even more exciting and promising aspect of this work is the possibility that IGF1 or similar therapeutics could apply not only to autism caused by Rett Syndrome, but also to other causes of autism as well."


'/>"/>

Contact: Kathryn Morris
kathryn@kmorrispr.com
845-635-9828
Autism Consortium
Source:Eurekalert

Related medicine news :

1. Los Angeles Dodger Matt Kemp and Dave Stewart Top Celebrity List to Raise Funds for Autism
2. 2 Genes Implicated in Autism
3. ToysRUs, Inc. Expands Its Support of Autism Speaks
4. Maximum Potential Offers Affordable Training Course for Parents of Children with Autism
5. New study explores the relationship between preterm birth and autism spectrum disorder
6. Upcoming Packard/Stanford Autism Symposium a Catalyst for Collaboration among Researchers and Community
7. Talk About Curing Autism Receives $300,000 Grant From Pacific Life Foundation to Provide Services for Families Affected by Autism in Orange County
8. Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town
9. Federal Members of Advisory Committee Block Vaccine-Autism Research, Defy Wishes of Its Own Scientists, Autism Community, and Congress
10. Saliva Test Could Indicate Autism
11. Tampa is Latest Recipient of Project Lifesaver Grant Funds Through The National Autism Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Silverado today is pleased ... open and operate a state-of-the-art memory care community in Alexandria, Virginia. The new community ... site just outside of Old Town. , The three-story community with underground parking ...
(Date:2/20/2017)... Pittsburgh, PA (PRWEB) , ... February 20, 2017 , ... ... mechanism of thyroid cancer, as well as a marker that may predict response to ... those with many other types of cancer as well. The new findings were published ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, ... Document Router (BDR), the first IoT device from Biscom designed to deliver confidential ... will debut BDR at HIMSS17 and will be conducting demonstrations at ...
(Date:2/20/2017)... ... 2017 , ... ReportingMD, a Population Health Software Company, is pleased to announce a move to ... location will triple the size of the previous location while bringing life back to a ... , “We are excited to expand our footprint to better serve our growing client ...
(Date:2/20/2017)... , ... February 20, 2017 , ... Chuck E. Cheese’s® ... Sensitive Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, New ... special needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s in ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... , February 20, 2017 ...  is anticipated to reach USD 1.4 billion by ... View Research, Inc. Constant evaluation of various techniques ... expected to drive growth in this market. Moreover, ... development of novel and improved shunts in order ...
(Date:2/20/2017)... New York , February 20, 2017 ... regularized absorption of calcium and phosphorous minerals in one,s ... of vitamin D ingredients in maintaining a healthy composition ... medicines containing vitamin D ingredients is growing in the ... advantage of consuming vitamin D ingredients for treatment of ...
(Date:2/19/2017)... , Feb. 19, 2017   AC Group ... selection, and ranking of vendors in the PMS/EHR healthcare ... and implementational system requirements to succeed in this ecosystem ... Group gathered together information obtained from over 200 ACOs, ... technology software and services companies that are providing different ...
Breaking Medicine Technology: